Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat Sodium Add-On Therapy in Spontaneous Intracerebral Hemorrhage
ChiCTR2600122007Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in intracerebral hemorrhage (ICH) comparing Intervention Group (Sivelestat Sodium) with Control Group (Placebo) (2 arms). Primary endpoint: Adverse functional outcomes at 90 days after onset. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2600122007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122007.